| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1038/NRRHEUM.2011.53 |
| P698 | PubMed publication ID | 21519352 |
| P50 | author | Cem Gabay | Q66753936 |
| P2093 | author name string | Gaby Palmer | |
| P2860 | cites work | IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines | Q24294720 |
| Nuclear expression of interleukin-33 in pancreatic stellate cells. | Q54657851 | ||
| Tissue Distribution and Subcellular Localization of a Variant Form of the Human ST2 Gene Product, ST2V | Q56593773 | ||
| IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy | Q57231967 | ||
| Caspase-1, Caspase-8, and Calpain Are Dispensable for IL-33 Release by Macrophages | Q57273017 | ||
| IL-33 can promote survival, adhesion and cytokine production in human mast cells | Q57273112 | ||
| The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis | Q61733657 | ||
| T1-deficient and T1-Fc-transgenic mice develop a normal protective Th2-type immune response following infection with Nippostrongylus brasiliensis | Q74164997 | ||
| Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation | Q74235980 | ||
| T1/ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation | Q80094797 | ||
| Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system | Q81191920 | ||
| IL-33 induces IL-13-dependent cutaneous fibrosis | Q82370239 | ||
| Association of serum interleukin-33 level and the interleukin-33 genetic variant with Japanese cedar pollinosis | Q82747179 | ||
| Increased serum levels of soluble ST2 in birch pollen atopics and individuals working in laboratory animal facilities | Q82793259 | ||
| CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation | Q82873698 | ||
| CpG oligodeoxynucleotides induce strong up-regulation of interleukin 33 via Toll-like receptor 9 | Q83009701 | ||
| Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis | Q83398961 | ||
| Over-expression of IL-33 leads to spontaneous pulmonary inflammation in mIL-33 transgenic mice | Q84095633 | ||
| IL-33 raises alarm | Q84233658 | ||
| Contribution of IL-33 to induction and augmentation of experimental allergic conjunctivitis | Q84299751 | ||
| Elevated Serum Interleukin 33 Is Associated with Autoantibody Production in Patients with Rheumatoid Arthritis | Q84650982 | ||
| IL-33 Exacerbates Eosinophil-Mediated Airway Inflammation | Q84698017 | ||
| Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling | Q84916626 | ||
| Active caspase-1 is a regulator of unconventional protein secretion | Q24308770 | ||
| IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation | Q24309034 | ||
| Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket | Q24321867 | ||
| A novel IL-1 family cytokine, IL-33, potently activates human eosinophils | Q24647672 | ||
| Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes | Q24649639 | ||
| The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1 | Q24651453 | ||
| T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function | Q24651566 | ||
| IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells | Q24652221 | ||
| Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules | Q24685626 | ||
| IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex | Q28239351 | ||
| ST2: a novel remodeling biomarker in acute and chronic heart failure | Q28280799 | ||
| Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems | Q28294477 | ||
| IL-33 mediates inflammatory responses in human lung tissue cells | Q28295034 | ||
| IL-33, a potent inducer of adaptive immunity to intestinal nematodes | Q28505946 | ||
| IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells | Q28513686 | ||
| Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor | Q28579840 | ||
| IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system | Q28585033 | ||
| Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation | Q28586791 | ||
| The cloning and nucleotide sequence of human ST2L cDNA | Q28593027 | ||
| IL-33 reduces the development of atherosclerosis | Q28594104 | ||
| Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis | Q30434426 | ||
| The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? | Q33374001 | ||
| Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population | Q33392397 | ||
| Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells | Q33508406 | ||
| Soluble ST2 plasma concentrations predict mortality in severe sepsis | Q33722112 | ||
| Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages | Q33722773 | ||
| IL-33 shifts macrophage polarization, promoting resistance against Pseudomonas aeruginosa keratitis | Q33845161 | ||
| The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response | Q33936725 | ||
| IL-33 is a crucial amplifier of innate rather than acquired immunity | Q34276672 | ||
| Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. | Q34358060 | ||
| Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli | Q34431061 | ||
| Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction | Q34603397 | ||
| The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses | Q34708854 | ||
| IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo | Q35575987 | ||
| T1/ST2--an IL-1 receptor-like modulator of immune responses. | Q35757164 | ||
| Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes | Q36101730 | ||
| Alarmins: chemotactic activators of immune responses | Q36162859 | ||
| IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice | Q36497523 | ||
| IL-33 exacerbates antigen-induced arthritis by activating mast cells | Q36800502 | ||
| Induction of IL-33 expression and activity in central nervous system glia | Q36838536 | ||
| Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. | Q36891595 | ||
| Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. | Q37100750 | ||
| The cytokine interleukin-33 mediates anaphylactic shock | Q37238924 | ||
| IL-33-activated dendritic cells induce an atypical TH2-type response | Q37265087 | ||
| A signal-switch hypothesis for cross-regulation of cytokine and TLR signalling pathways | Q37267214 | ||
| Interleukin-33 is biologically active independently of caspase-1 cleavage | Q37339298 | ||
| IL-18 and IL-33 elicit Th2 cytokines from basophils via a MyD88- and p38alpha-dependent pathway | Q37362940 | ||
| Interleukin-33 - cytokine of dual function or novel alarmin? | Q37440227 | ||
| IL-33 and IL-33 receptors in host defense and diseases | Q37736212 | ||
| The biological paths of IL-1 family members IL-18 and IL-33 | Q37800776 | ||
| Intracellular signaling mechanisms regulating the activation of human eosinophils by the novel Th2 cytokine IL-33: implications for allergic inflammation | Q39026926 | ||
| Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro | Q39583710 | ||
| Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells | Q39645392 | ||
| A novel method for procuring a large quantity of mature murine eosinophils in vivo | Q39648956 | ||
| IL-33 reduces macrophage foam cell formation. | Q39693915 | ||
| KU812 cells provide a novel in vitro model of the human IL-33/ST2L axis: functional responses and identification of signaling pathways | Q39712768 | ||
| Expression and regulation of interleukin-33 in human monocytes. | Q39752500 | ||
| Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation | Q39758961 | ||
| Mature interleukin-33 is produced by calpain-mediated cleavage in vivo | Q39825950 | ||
| IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex | Q39833597 | ||
| TRAF6 is a critical signal transducer in IL-33 signaling pathway | Q39964682 | ||
| The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. | Q39986449 | ||
| Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells | Q40049209 | ||
| Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production | Q42629896 | ||
| IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production | Q42630793 | ||
| Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. | Q42733194 | ||
| IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling | Q42816541 | ||
| Murine ST2 gene is a member of the primary response gene family induced by growth factors | Q42819569 | ||
| JAK2 is an important signal transducer in IL-33-induced NF-κB activation | Q42819596 | ||
| T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses | Q42944108 | ||
| Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. | Q42947124 | ||
| The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function | Q42947210 | ||
| Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection | Q43062147 | ||
| IL-33 prolongs murine cardiac allograft survival through induction of TH2-type immune deviation | Q43134557 | ||
| The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. | Q43143737 | ||
| IL-33 exacerbates autoantibody-induced arthritis | Q43170043 | ||
| Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus | Q43212382 | ||
| ST2 deficient mice display a normal host defense against pulmonary infection with Mycobacterium tuberculosis | Q43583400 | ||
| IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals | Q43690957 | ||
| Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. | Q44030778 | ||
| Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction | Q44245130 | ||
| IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. | Q45067212 | ||
| An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor | Q46305097 | ||
| A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. | Q47310105 | ||
| IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. | Q47944333 | ||
| Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma | Q48022100 | ||
| IL-33 receptor (T1/ST2) signalling is necessary to prevent the development of encephalitis in mice infected with Toxoplasma gondii | Q48393870 | ||
| The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. | Q51780702 | ||
| Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. | Q53258549 | ||
| Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. | Q53359649 | ||
| Modulation of interleukin signalling and gene expression in cardiac myocytes by endothelin-1. | Q53363430 | ||
| IL-33 is a chemoattractant for human Th2 cells. | Q53528244 | ||
| IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. | Q54421098 | ||
| Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. | Q54431742 | ||
| Increased IL-33 expression by epithelial cells in bronchial asthma. | Q54441538 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | interleukins | Q194908 |
| P304 | page(s) | 321-329 | |
| P577 | publication date | 2011-04-26 | |
| P1433 | published in | Nature Reviews Rheumatology | Q2107227 |
| P1476 | title | Interleukin-33 biology with potential insights into human diseases | |
| P478 | volume | 7 |
| Q58115501 | A FRET biosensor for necroptosis uncovers two different modes of the release of DAMPs |
| Q26823326 | A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis |
| Q53070656 | A network map of IL-33 signaling pathway. |
| Q41871362 | A20-deficient mast cells exacerbate inflammatory responses in vivo |
| Q35699580 | AMCase is a crucial regulator of type 2 immune responses to inhaled house dust mites |
| Q36744984 | Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33. |
| Q38287064 | Actual position of interleukin(IL)-33 in atherosclerosis and heart failure: Great Expectations or En attendant Godot? |
| Q34033407 | Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity |
| Q38530106 | Alarmin' Immunologists: IL-33 as a Putative Target for Modulating T Cell-Dependent Responses |
| Q47347447 | Alarmins in Frozen Shoulder: A Molecular Association Between Inflammation and Pain |
| Q40473630 | Altered Treg and cytokine responses in RSV-infected infants. |
| Q42150863 | Atherosclerosis severity is not affected by a deficiency in IL-33/ST2 signaling |
| Q34304314 | Basophil modulation by cytokine instruction |
| Q38732306 | CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm |
| Q41464455 | Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation |
| Q53053910 | Changes in inflammatory mediators as a result of intermittent hypoxia in obstructive sleep apnea syndrome. |
| Q36618926 | Changes in serum Interleukin-33 concentration before and after treatment with pegylated interferon alfa-2a plus ribavirin in patients with chronic hepatitis C genotype 1b infection |
| Q36179133 | Cooperation between the bacterial-derived short-chain fatty acid butyrate and interleukin-22 detected in human Caco2 colon epithelial/carcinoma cells |
| Q37987351 | Current understanding of rheumatoid arthritis therapy |
| Q36903150 | Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency |
| Q34540500 | Disordered IL-33/ST2 activation in decidualizing stromal cells prolongs uterine receptivity in women with recurrent pregnancy loss |
| Q92251945 | Dynamic changes of soluble ST2 levels predicted fatality and were involved in coagulopathy in dengue fever in the elderly |
| Q36444778 | Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. |
| Q41297752 | Epidermal Expression and Regulation of Interleukin-33 during Homeostasis and Inflammation: Strong Species Differences |
| Q48120429 | Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer. |
| Q35618798 | Experimental Models of Inflammatory Bowel Diseases |
| Q34149191 | Expression of IL-33 and its epigenetic regulation in Multiple Sclerosis |
| Q36025690 | Galectin-3 Ablation Enhances Liver Steatosis, but Attenuates Inflammation and IL-33-Dependent Fibrosis in Obesogenic Mouse Model of Nonalcoholic Steatohepatitis |
| Q37231684 | High-density genotyping study identifies four new susceptibility loci for atopic dermatitis |
| Q44761350 | Human mesenchymal stem cells overexpressing the IL-33 antagonist soluble IL-1 receptor-like-1 attenuate endotoxin-induced acute lung injury |
| Q36694205 | IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells |
| Q36005876 | IL-1 family members in the pathogenesis and treatment of metabolic disease: Focus on adipose tissue inflammation and insulin resistance |
| Q38722744 | IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer. |
| Q60909064 | IL-33 ameliorates experimental colitis involving regulation of autophagy of macrophages in mice |
| Q47718005 | IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer |
| Q36512087 | IL-33 drives biphasic IL-13 production for noncanonical Type 2 immunity against hookworms |
| Q53077975 | IL-33 enhances proliferation and invasiveness of decidual stromal cells by up-regulation of CCL2/CCR2 via NF-κB and ERK1/2 signaling. |
| Q35691155 | IL-33 receptor ST2 amplifies the expansion of NK cells and enhances host defense during mouse cytomegalovirus infection |
| Q92335370 | IL-33/ST2 axis promotes glioblastoma cell invasion by accumulating tenascin-C |
| Q41036719 | IL-4 production by group 2 innate lymphoid cells promotes food allergy by blocking regulatory T-cell function. |
| Q46866026 | IL‑33 enhances glioma cell migration and invasion by upregulation of MMP2 and MMP9 via the ST2-NF-κB pathway |
| Q34736360 | Impaired colonic B-cell responses by gastrointestinal Bacillus anthracis infection |
| Q36807908 | Implications for Interleukin-33 in solid organ transplantation |
| Q47106942 | Increased plasma IL-17, IL-31, and IL-33 levels in chronic spontaneous urticaria |
| Q33898659 | Indoleamine 2,3-dioxygenase-1 (IDO1) in human endometrial stromal cells induces macrophage tolerance through interleukin-33 in the progression of endometriosis |
| Q26858882 | Innate immunity in the central nervous system |
| Q36597506 | Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells |
| Q38702558 | Interleukin 33 is a guardian of barriers and a local alarmin |
| Q33987547 | Interleukin 33: a switch-hitting cytokine |
| Q60046076 | Interleukin-33 Contributes Toward Loss of Tolerance by Promoting B-Cell-Activating Factor of the Tumor-Necrosis-Factor Family (BAFF)-Dependent Autoantibody Production |
| Q36228512 | Interleukin-33 and RANK-L Interplay in the Alveolar Bone Loss Associated to Periodontitis |
| Q59351894 | Interleukin-33 and ST2 Signaling in Tumor Microenvironment |
| Q59354754 | Interleukin-33 contributes to disease severity in Dengue virus infection in mice |
| Q36751804 | Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer. |
| Q35754479 | Interleukin-33 in Tissue Homeostasis, Injury, and Inflammation |
| Q39653025 | Interleukin-33 in human gliomas: Expression and prognostic significance |
| Q36585708 | Interleukin-33 in the human placenta |
| Q40972417 | Interleukin-33 promotes Th2 immune responses in infected mice with Schistosoma japonicum |
| Q33678403 | Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease |
| Q41945735 | Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis |
| Q38770982 | Interleukin-33: increasing role in dermatological conditions |
| Q34544863 | Intracellular function of interleukin-1 receptor antagonist in ischemic cardiomyocytes |
| Q41475075 | Loss of interleukin 33 expression in colonic crypts - a potential marker for disease remission in ulcerative colitis |
| Q40367971 | Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia - a longitudinal study |
| Q92857768 | Memory CD8+ T Cell Protection From Viral Reinfection Depends on Interleukin-33 Alarmin Signals |
| Q92479800 | Molecular mechanisms regulating immune responses in thromboangiitis obliterans: A comprehensive review |
| Q37617670 | Murine mast cells secrete and respond to interleukin-33 |
| Q37706803 | Positive selection of IL-33 in adaptive immunity of domestic Chinese goats. |
| Q37192446 | Potential of IL-33 for Preventing the Kidney Injury via Regulating the Lipid Metabolism in Gout Patients. |
| Q36516498 | Prostaglandin I2 Signaling and Inhibition of Group 2 Innate Lymphoid Cell Responses. |
| Q92862530 | Rheumatiod Arthritis: An Updated Overview of Latest Therapy and Drug Delivery |
| Q33854499 | Role of IL-33 and its receptor in T cell-mediated autoimmune diseases |
| Q37620811 | Role of the IL-33-ST2 axis in sepsis |
| Q27679811 | Structural insights into the interaction of IL-33 with its receptors |
| Q35279922 | T-bet- and STAT4-dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses. |
| Q35972372 | TLR3 Agonist Poly-IC Induces IL-33 and Promotes Myelin Repair |
| Q30486741 | The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors |
| Q37174541 | The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani |
| Q40823404 | The TAK1→IKKβ→TPL2→MKK1/MKK2 Signaling Cascade Regulates IL-33 Expression in Cystic Fibrosis Airway Epithelial Cells Following Infection by Pseudomonas aeruginosa. |
| Q35116283 | The alarmin IL-33 promotes regulatory T-cell function in the intestine |
| Q38131032 | The alarmin functions of high-mobility group box-1 and IL-33 in the pathogenesis of systemic lupus erythematosus. |
| Q38979165 | The danger from within: alarmins in arthritis |
| Q38530866 | The diverse role of RIP kinases in necroptosis and inflammation |
| Q21131158 | The environment of regulatory T cell biology: cytokines, metabolites, and the microbiome |
| Q38967737 | The epithelial barrier and immunoglobulin A system in allergy |
| Q37085681 | The histone deacetylase inhibitor trichostatin A suppresses murine innate allergic inflammation by blocking group 2 innate lymphoid cell (ILC2) activation |
| Q24633658 | The immune pathogenesis of scleroderma: context is everything |
| Q42496270 | The mouse interleukin (Il)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promoters |
| Q38424483 | The potential role of IL-33/ST2 signaling in fibrotic diseases |
| Q35373060 | The sterile inflammation in the exacerbation of HBV-associated liver injury |
| Q58104422 | Type 2 Innate Lymphoid Cells Impede IL-33-Mediated Tumor Suppression |
| Q28082245 | Type 2 responses at the interface between immunity and fat metabolism |
| Q30807010 | Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial |
Search more.